Fonte
biopharmadive.com
38articoli totali nell'archivio
Supreme Court preserves access to abortion pill by mail
The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail…
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its…
Create Medicines raises $122M to bolster in vivo CAR-T therapies
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
FDA’s leadership void leaves biotech with renewed ‘uncertainty’
Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted…
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could…
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with…
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved…
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2…
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese…
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Odyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech…
Sarepta tumbles as its gene therapy sales decline further
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA…
Entrada shares dive as Duchenne results disappoint
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares…
Roche to acquire digital pathology firm PathAI in deal potentially worth over…
Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
Biotech M&A is accelerating. Track the deals that are happening here.
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Novo hikes guidance on Wegovy pill’s fast sales start
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally…
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to…
10 clinical trials to watch in the first half of 2026
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Drugs from China are reshaping biotech. Track the licensing deals here.
Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing…